Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus
Status:
Terminated
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see whether the combination of selinexor (KPT-330) and
irinotecan can help people with esophageal or stomach cancer. Researchers also want to find
out if the combination of selinexor (KPT-330) and irinotecan is safe and tolerable.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute